We treated human GBM cell lines A172 and U251 with GSK126 in the presence and absence of IFNγ, a known inducer of CXCL9 and CXCL10 expression (Supplementary Figures 1A, B) (21). The gene discussed is CXCL9; the disease is glioblastoma.